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Comment on Yamanaka: Dendritic cell and peptide based vaccination strategies for glioma 
 
 
Malignant gliomas remain a major challenge in the field of neurooncology. Despite 
multimodal therapy, including surgical resection, radio- and chemotherapy along with the 
identification of predictive markers for response to treatment such as the epigenetic silencing 
of the O6-methylguanine-DNA methyltransferase (MGMT) gene, the prognosis for the 
affected patients has only been slightly improved. Novel therapeutic approaches include 
targeted therapies such as the administration of small molecules or monoclonal antibodies that 
inhibit their target specifically. Exquisite specificity is also one of the hallmarks of the 
immune system which is therefore regarded as a potential and extremely precise weapon 
against tumors. The various alterations that are expressed by malignant glioma cells may, in 
general, provide antigenic targets for recognition by the immune system. However, as proven 
by the clinical course, gliomas hide from the immune system and further avoid immune attack 
by various immunosuppressive mechanisms. Harnessing the immune system against these 
tumors by overcoming such obstacles may therefore be a promising therapeutic approach.  
Here, the author provides a detailed overview on dendritic cell (DC)- and peptide-based 
immunotherapeutic strategies, important pitfalls and an overview on future directions. DC and 
peptide vaccination have entered the clinic within the last ten years. Until today, the general 
experience with such therapeutic approaches has shown excellent tolerability, immune 
responses against the vaccine, but only few favourable clinical responses. The disappointing 
results of these studies has probably several reasons, including a lack of immunogenicity of 
tumor cells, inadequate adjuvants or too low levels of antigens of value. Additionally, there 
might be tumor cells that are particularly resistant to an attack by the immune system. With 
the identification of tumor-initiating cells with stem cell properties within gliomas, a 
population of cells has been identified that may contribute to this immunoresistance. These 
“stem-like cells” may also explain the inevitable recurrence of gliomas and define these cells 
as novel targets to overcome the resistance to conventional and immunotherapy in this 
disease. Based on these novel insights of glioma biology, future immunotherapeutic strategies 
against malignant gliomas targeting specifically glioma-initiating cells might be more 
successful than previous approaches. The optimization of vaccination protocols includes 
further steps such as the selection of “personalized” peptides and a modulation of tumor-
associated immunosuppression. Given these considerations, one can optimistically await 
future immunotherapeutic clinical trials for glioma patients. 
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